Clinical Trial Detail

NCT ID NCT02610777
Title An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Indications

bone marrow cancer

acute myeloid leukemia

myelodysplastic syndrome

Therapies

Azacitidine

MLN4924

Age Groups: adult

No variant requirements are available.